Published in Women's Health Weekly, December 4th, 2003
"We are extremely pleased the FDA has cleared us to begin this trial and look forward to establishing tesmilifene's ability to enhance traditional chemotherapies and extend the survival time of women with metastatic breast cancer, as the drug has demonstrated in a previous phase III trial," said David Allan, chairman and chief executive officer of YM BioSciences.
"The incorporation of a sequential design into...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly